Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;24(7):835-847.
doi: 10.1080/14656566.2023.2199921. Epub 2023 Apr 19.

The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder

Peter J Castagna  1 , Elita Farahdel  2 , Marc N Potenza  1   3   4   5   6   7 , Michael J Crowley  1
Affiliations

The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder

Peter J Castagna et al. Expert Opin Pharmacother. 2023 May.

Abstract

Introduction: Anxiety disorders are the most prevalent psychiatric disorders among youth. Among the various anxiety disorders, generalized anxiety disorder is particularly prevalent. Youth with GAD appear at elevated risk of developing other anxiety disorders, mood disorder, and substance use disorders. Functional outcomes of youth with GAD can be improved through early recognition and treatment, thus promoting better longer-term outcomes.

Areas covered: The current article summarizes evidence-based state-of-the-art pharmacotherapy for pediatric GAD based on open-label, randomized, and controlled trials. Two electronic databases (PubMed and Scopus) were systematically searched in April 2022 for relevant publications.

Expert opinion: The literature supports a combination of psychotherapy and pharmacotherapy as being associated with better outcomes when compared to mono-therapies. While longer-term follow-ups are limited, one such study does challenge this notion. Both selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs) have been found across studies to have moderate effect sizes in the treatment of pediatric anxiety disorders. SSRIs continue to be a first-line intervention, whereas SNRIs may be considered a second-line treatment. While more evidence is needed, there are emerging data indicating that SSRIs are associated with a more rapid and greater reduction in anxiety symptoms when compared to SNRIs.

Keywords: Pharmacotherapy; SNRI; SSRI; generalized anxiety; medication; pediatric anxiety.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA flow diagram for new systematic reviews which included searches of databases and registers only (Page et al., 2021).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ezpeleta L, et al., Epidemiology of psychiatric disability in childhood and adolescence. The Journal of Child Psychology and Psychiatry and Allied Disciplines, 2001. 42(7): p. 901–914. - PubMed
    1. Costello EJ, et al., Prevalence and development of psychiatric disorders in childhood and adolescence. Archives of general psychiatry, 2003. 60(8): p. 837–844. - PubMed
    1. Costello EJ, Copeland W, and Angold A, Trends in psychopathology across the adolescent years: what changes when children become adolescents, and when adolescents become adults? Journal of Child Psychology and Psychiatry, 2011. 52(10): p. 1015–1025. - PMC - PubMed
    1. Merikangas KR, et al., Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A). Journal of the American Academy of Child & Adolescent Psychiatry, 2010. 49(10): p. 980–989. - PMC - PubMed
    1. Kendall, et al., Child anxiety treatment: outcomes in adolescence and impact on substance use and depression at 7.4-year follow-up. Journal of consulting and clinical psychology, 2004. 72(2): p. 276. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources